Six month target for validating lab data, twelve month target for completion of platform
Daryl Thompson’s pandemics technology, used to fight Ebola (pictured), will influence development of the universal drug. Photo by CDC/Cynthia Goldsmith, via Wikimedia Commons
Singapore eDevelopment (SeD) has initiated advanced research on a new universal therapeutic drug platform known as Linebacker, to combat a range of diseases including Alzheimer's, diabetes and cancer.
Unlike curing individual diseases with specific drugs, the Linebacker platform seeks a breakthrough option to cure multiple diseases. It can also potentially combat drug-resistant viruses and antibiotic-resistant bacteria.
Two-time Nobel Prize nominee and Director of Scientific Initiatives, Daryl Thompson, will lead the research, with the SeD subsidiary, Global BioLife.
Thompson was nominated for a Nobel Prize in 2015 and 2016 for his research in cutting-edge organic and carbohydrate chemistry as well his research in pandemics technology to fight pandemics such as Ebola.
He has used his expertise to initiate research regarding universal therapeutics to cure the world's deadliest diseases. Scott Truesdell, Research Coordinator and Special Projects Leader at Global BioLife, will execute the research on the Linebacker platform.
Thompson said: “We expect to obtain validating laboratory data from the universal therapeutic drug platform within the first six months and are targeting for the platform itself to be completed within twelve months.”
“We have a unique patented technology and are already getting interest from Big Pharma players and venture capitalists. This interest will rise as the validating data becomes available.”